替罗非班对非介入治疗急性非ST段抬高心肌梗死患者的疗效

摘要

Objective To study the efficiency and safety of Tirofiban for patients with NSTEMI and non -invasive therapy.Methods 80 patients with NSTEMI and without earlier reperfusion therapy treated from January 2013 to Sep-tember 2014 in our hospital were selected and randomly divided into control group and research group , 40 cases each group.The control group received the conventional treatment while the research group received the conventional treatment combined with Tirofiban; the variations and hemorrhage of cardiovascular events like death , MI and LVEF were ob-served.Results One patient of control group was died of cerebral hemorrhage ( P>0.05 ); the research group had no death or major bleeding case .In the periodic checkup , there were 2 cases died of MI and 3 cases with LVEF (<40%) (P<0.05).Conclusions The findings indicate that Tirofiban can partially improve the clinical symptoms and left ven -tricular ejection for patients with NSTEMI .The major adverse cardiovascular events were not greatly improved .It pro-vides the clinical basis to make the best medication treatment for patients with STEMI and without reperfusion therapy . However , it needs to be further explored .%目的：探讨未行早期介入治疗的急性非ST段抬高心肌梗死（ NSTEMI）患者替罗非班应用的有效性和安全性。方法选取2013年1月～2014年9月收治的未行早期再灌注治疗NSTEMI患者80例，随机分为对照组和研究组，每组40例，对照组行常规治疗，研究组在对照组治疗方案基础上加用替罗非班治疗，观察两组间死亡、再次心肌梗死及左室射血分数等心血管临床事件的变化及出血情况。结果对照组1例脑出血死亡（P＞0．05），研究组无死亡及严重出血事件，随诊再次发生心肌梗死2例，射血分数＜40％者3例，明显优于对照组（ P＜0．05）。结论研究结果表明替罗非班一定程度上改善了NSTEMI患者的临床症状和左室射血功能，但对于主要不良心血管事件的发生率无明显改善。对未行急诊再灌注治疗的STEMI的最佳药物治疗方案制订提供了一定的临床依据，但仍需进一步探索。